Purpose: Since the modulation factor (MF) impacts both plan quality and delivery efficiency in tomotherapy Intensity Modulated Radiation Therapy (IMRT) treatment planning, the purpose of this study was to demonstrate a technique in determining an efficient MF from the Multileaf Collimator (MLC) leaf-open time (LOT) distribution of a tomotherapy treatment delivery plan.
| INTRODUCTION
Helical tomotherapy (HT) delivers radiation therapy through synchronization of the binary Multileaf Collimator (MLC) leaf-pair openings, gantry rotation period, and couch longitudinal speed. Highly conformal dose distributions can be achieved through intensity modulation of the HT radiation field. The HT radiation field is divided into 51 projections per gantry rotation (7.06°of gantry rotation per projection).
Each projection is further divided into 64 beamlets representing each of the 64 MLC binary leafs (i.e., the leaf being either open or closed).
The leaf-open time (LOT) of each beamlet that intersects a target volume determines the instantaneous radiation dose delivered from it through the projection arc or fraction thereof. Intensity-modulated radiation therapy (IMRT) is achieved by varying the LOT of each beamlet with inverse-planning optimization of the treatment plan.
Inverse-planning optimization for Tomotherapy requires the planner to choose a modulation factor (MF) that is defined as
where LOT max is the maximum LOT and LOT mean is the average of all beamlet LOTs. 1 The MF is a parameter that influences the complexity of intensity-modulated radiation field and a higher MF may result in a more conformal, homogeneous target dose distribution and improved sparing of critical structures. High MF values are typically used for plans with irregular-shaped planning target volumes (PTV) and critical structures that are either adjacent or overlapping. 1 A high MF allows greater freedom for the optimizer to vary LOTs for beamlets.
Modulation factor (MF) values reported in literature vary with institution, treatment site, and type of study. MFs reported for several prostate studies range from 1.8 to 3.5 with 2.5 being the most common factor. [2] [3] [4] [5] [6] MFs reported for several head-and-neck (HN) studies range from 2.0 to 3.5. [7] [8] [9] [10] [11] MFs for several gynecological (GYN) studies ranged from 3.0 to 4.0. 12, 13 Most recently Shimizu et al. retrospectively analyzed the MF used in 293 HN plans and 181 prostate plans to derive an initial MF (2.1 and 1.8, respectively) and upper limit MF (2.6 and 2.2, respectively) specific to the treatment site. 14 The MF has a direct impact on treatment delivery time. Because the linear accelerator dose rate, couch speed, and gantry period are constant during helical treatment delivery, the total time for "beamon" delivery is a product of number of gantry rotations and gantry period,
Total delivery time ¼ active gantry rotations Â gantry period: (2) The number of gantry rotations is determined by the pitch and the length of cranial-caudal treatment volume plus jaw width. The gantry period is equal to 51 × LOT max , unless LOT max is <235 ms, in which case the gantry period minimum has been reached at 11.8 s.
Therefore, for gantry periods above 11.8 s,
Total delivery time ¼ 51 Â LOT max Â active gantry rotations:
A high MF value can allow the optimizer to generate beamlets with long LOTs that have minimal impact on the dose distribution. 15 It has been suggested for complex plans that planners start with a high MF to achieve a good conformal plan and then reduce the MF until the dosimetric qualities of the plan degrade to clinically unacceptable values. 9, 16 This paper presents a heuristic approach for determining a MF from the first two moments of the LOT distribution of a plan optimized with the highest allowed MF. A technique is then used to determine a set of MFs for subsequent "reduced-MF" plan calculations to find a balance between dosimetric quality and treatment delivery time. Table 1 lists the six treatment cases of varying complexity that were used to demonstrate the proof of concept for determining the MF from the moments of the LOT distribution. These plans were taken from actual treatments with same planning structure sets and jaw widths as the original plans. In our clinic we typically use 2.5-cm jaw width for prostate and HN patients and 5.0-cm jaw widths for GYN cases with para-aortic nodal involvement. A pitch value of 0.43, determined from the 0.86/n formula by Kisseck et al, was used for all plans. 17 No significant dose distribution threading effects were seen with the plans. All treatments utilized dynamic jaws. 18 Plans were generated with the Precision treatment planning system (TPS) version 1.0.0.2 (Accuray, Sunnyvale, CA) using VoLO, a GPU-based optimizer incorporating a non-voxel based algorithm. 19 VoLO has been shown to produce dosimetrically equivalent plans compared to the original voxel-based optimization algorithm in a fraction of the computation time. 20 Although this approach for determining the MF is valid for the original Tomotherapy TPS, the Precision TPS is ideal for this process in that (a) the moments of the LOT distribution are displayed with the distribution in the graphics user interface and (b) two plans can easily be compared with each other with the Precision plan evaluation feature. Figure 1 shows the Precision TPS "Dx Vx
| MATERIALS AND METHODS
Value" table that allows a user to observe specific dose-volume values of a plan and comparative differences with a reference plan.
2.A | MF determination from LOT distribution
In the planning system the LOT histogram is described by three parameters; its mean, mode, and standard deviation. In our approximation we have set the mean of our un-normalized Gaussian equal to the mean of the LOT distribution and have taken the standard deviation of LOT distribution as its standard deviation.
Using this approximation to the LOT distribution, as one is justified to do by the central limit theorem, one can easily calculate a cutoff LOT max value that eliminates the upper tail of LOTs using the following equation,
where LOT Mean,final is the mean of the LOT distribution after final dose calculation, and LOT Std,final is the standard deviation after final dose calculation, and z critical is the critical z-value corresponding to percentage of upper LOTs that would be filtered from a true Gaussian distribution (Table 2 ). This LOT max value was then used in Eq.
(1) to determine the MF for subsequent "reduced-MF plan" calculations. However, to maintain LOT Max cutoff value, and therefore the intended reduced delivery time, the mean of the optimization LOT distribution was used to calculate MF, that is,
This is done because the mean of the LOT distribution shifts as a result of inclusion of the bins with less than 20 ms in determining the mean of the distribution. While the final deliverable MF is less than or equal to the planning MF because of exclusion of bins with less than 20 ms, but both share the same LOT max value, which is what we are adjusting to find an efficient "beam-on" delivery time.
This lower leaf open time cutoff is due to the 20-ms transit time of MLC leaf opening and closing.
2.B | Progressive MF reduction
A reference plan was generated with highest MF allowed (MF = 5) using 300 iterations for the simple prostate plans and 500 iterations for more complex simultaneous integrated boost (SIB) plans with the exception of one HN plan (6.b) that was optimized with 2000 iterations to compare with the same plan optimized with 500 iterations (6.a). Optimization was done at medium resolution (1.96 mm × 2.5 mm × 1.96 mm) and final dose calculation was done at high resolution (0.98 mm × 2.5 mm × 0.98 mm). LOT Mean,final ; LOT Mean,opt ; and LOT Std,final from the reference plan LOT distribution were used to generate five levels of modulation (Table 2) for subsequent reduced-MF plan calculations starting with MF(z critical = 2.33) and stepping down to MF(z critical = 0.86) with 50 iterations per step.
After the reference plan was generated dose-volume region of interests (ROIs) were established in the Precision Dx Vx Table 4 lists the reduced MF as a function of the z critical score using Eq. (5) for each reference plan and associated LOT standard deviation along with the estimated time of delivery using Eq. (3); the entry in bold is the lowest MF that maintained ROI dose-difference tolerances with the reference plan. Also listed in Table 4 are the fraction of LOT events in the LOT max bin. These values are slightly higher than those listed in Table 2 , especially for more complex plans, but do seem to indicate that the central limit theorem is valid in describing the LOT distribution. the prostate and SIB plans was 300 and 500, respectively, was (a) that in our experience these values lead to convergence to a good plan and (b) to insure that the LOT distribution had sufficiently settled into a linear increase in standard deviation with number of optimization iterations. Oliver et al also found convergence with phantom plans using 250 iterations. 21 what is remarkable is that lowest LOT-generated MF with dosevolume ROIs within dose-difference tolerances is at a z critical = 1.28, and delivery efficiency is achieved. 9 The methodology presented in this paper provides the user with a stepwise MF reduction scheme that should achieve such a balance within a few steps.
| RESULTS

3.A | Prostate plans
3.B | SIB plans
Plan evaluation and acceptance criteria can vary depending on individual clinical expectations and dosimetric quality trade-offs.
The criteria for plan comparison used in this study were chosen to find the best MF within a range of MFs using an established set of rules and are not meant to be standard practice for plan evalua- 
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